
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
C1-INH treatment shortened the mean duration of abdominal attacksfrom 92 to 40 hours and the mean maximal pain score declined from8.6 to 4.5.